PMID: 7580638Oct 14, 1995Paper

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group

BMJ : British Medical Journal
C C McDonaldH J Stewart

Abstract

To determine any cardiac or vascular morbidity associated with long term treatment with tamoxifen given after mastectomy for primary breast cancer. Cohort study using linkage between database of a randomised trial and statistics of Scottish hospital inpatients to identify episodes of cardiac and vascular morbidity. NHS hospitals in Scotland. 1312 women who had undergone mastectomy for breast cancer and who were randomised either to a treatment group to receive adjuvant tamoxifen or to a control group to be given tamoxifen only on first relapse of disease. Maximum duration of tamoxifen treatment was 14 years. Total woman years of follow up were 9943. Randomised and observational comparisons of risk (expressed as hazard ratios) of myocardial infarction, other cardiac event, cerebrovascular disease, or thromboembolic event according to treatment allocated and between nonusers, former users, and current users of tamoxifen. Use of tamoxifen was associated with lower rates of myocardial infarction. Hazard ratio for women in control group was 1.92 (95% confidence interval 0.99 to 3.73) compared with women allocated to adjuvant treatment. The association was stronger for current use: hazard ratio for non-users was 3.49 (1.52 to 8.03) c...Continue Reading

Citations

Feb 8, 2007·Pflügers Archiv : European journal of physiology·Pedro GeraldesAngelino Calderone
Jan 11, 2007·Breast Cancer Research and Treatment·Sonal Gandhi, Sunil Verma
Nov 21, 2007·Breast Cancer Research and Treatment·Edith A Perez
Mar 5, 2013·Breast Cancer Research and Treatment·Johan RosellJohn Carstensen
Feb 12, 2002·Lipids·M Cattaneo
Feb 2, 2002·Current Atherosclerosis Reports·Claire S Duvernoy, Lori Mosca
Jan 5, 2002·Current Atherosclerosis Reports·Howard N HodisRoger Lobo
Aug 7, 2002·Current Atherosclerosis Reports·Jennifer E Ho, Lori Mosca
Feb 4, 2003·Current Atherosclerosis Reports·Howard N HodisRoger Lobo
Dec 20, 2008·Advances in Therapy·Andrew M Wardley
Aug 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V J AssikisI Vergote
Jun 14, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Alberto RomeroMiguel-Angel González
Jun 19, 2004·International Journal of Cardiology·Jaffar Ali RazaAssad Movahed
Jun 1, 1997·Molecular Aspects of Medicine·V C Jordan, W J Gradishar
Mar 27, 2001·European Journal of Obstetrics, Gynecology, and Reproductive Biology·M Ursic VrscajV Robic
Oct 5, 2002·Cancer Treatment Reviews·M ClemonsA Howell
Oct 31, 2003·Critical Reviews in Oncology/hematology·Mario MandalàSandro Barni
Jan 12, 2002·Kidney International·Sergio StefoniSandra Iannelli
Sep 29, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A. H. N. UgwumaduP. Neven
Dec 23, 2003·Journal of General Internal Medicine·R Scott BraithwaiteNananda F Col
May 4, 2000·The New England Journal of Medicine·G C BlobeH F Lodish
Jun 30, 2001·The New England Journal of Medicine·C L Shapiro, A Recht
Dec 31, 2005·The New England Journal of Medicine·UNKNOWN Breast International Group (BIG) 1-98 Collaborative GroupAron Goldhirsch
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Dec 7, 2010·Cardiovascular Research·Gracia El Gebeily, Céline Fiset
Jun 4, 1997·Journal of the National Cancer Institute·V C Jordan
Jun 4, 1997·Journal of the National Cancer Institute·J P CostantinoJ Dignam
Jun 5, 2003·Journal of the National Cancer Institute·Andrea DecensiUmberto Veronesi
Nov 3, 2005·Journal of the National Cancer Institute·Bo NordenskjöldJohn Carstensen
Jul 12, 2011·Journal of the National Cancer Institute·Eitan AmirAlberto Ocaña
Jun 10, 2009·Mutagenesis·Karen Brown
Feb 16, 2005·Current Opinion in Obstetrics & Gynecology·Deepak GoyalGregory Y H Lip
Oct 17, 2001·Journal of Cardiovascular Pharmacology·S J HutchisonK Sudhir

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
H J Stewart
Scottish Medical Journal
A J Haddow
Journal of the National Cancer Institute
H J StewartA P Forrest
© 2021 Meta ULC. All rights reserved